{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:24:46Z","timestamp":1791440686737,"version":"4.3.3"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,12,19]],"date-time":"2021-12-19T00:00:00Z","timestamp":1639872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2021,12,19]],"date-time":"2021-12-19T00:00:00Z","timestamp":1639872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T00:00:00Z","timestamp":1671840000000},"content-version":"am","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jsm.jsexmed.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Some evidence suggests that intracavernosal botulinum toxin A (BTX-A IC) injections administered in addition to phosphodiesterase type 5 inhibitors (PDE5-Is) or prostaglandin E1 intracavernosal injections (PGE1 ICI) could effectively treat erectile dysfunction (ED) in non\u2013responders, or insufficient responders to these pharmacologic treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To determine the long-term effectiveness and safety of combined treatment involving a single injection of BTX-A IC as an add on therapy to PDE5-Is or PGE1-ICI for the treatment of ED of different etiologies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective, uncontrolled, single center study was conducted. Data from 123 consecutive patients with ED who were insufficient responders to PDE5-Is or PGE1-ICI and who received onabotulinumtoxinA 100 U, abobotulinumtoxinA 250 U or 500 U IC as an add on to their current pharmacologic treatment were analyzed. All analyses were exploratory. Qualitative data were compared using the Fisher\u2019s exact test. Univariate and multivariate analysis were performed using logistic regression with Odds Ratios (OR). Only variables with P &amp;lt; .05 in the univariate analysis were selected for multivariate analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The minimally clinically important difference (relative to baseline severity of ED) in the International Index of Erectile Function-Erectile function domain (IIEF-EF) score was achieved in 50% of patients at 34 (27\u201342) days and in 41% at 5.9 (3.9 \u2013 8.1) months following BTX-A IC in combination with PDE5-Is or PGE1 ICI. The severity of ED influenced response to BTX-A IC according to the multivariate analysis (OR = 0.3, IC(95%]) = (0.16 \u2013 0.56). Neither being post prostatectomy nor the type of BTX-A affected the response. Effectiveness tended to decrease more over time with abobotulinumtoxinA 250 U than 500 U.<\/jats:p>\n                    <jats:p>The only side-effects were mild penile pain on injection (n = 1) and mild penile pain for 3 days following injection (n = 1); no systemic effects were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical implications<\/jats:title>\n                    <jats:p>BTX-A IC (all types) administered as an add on to registered pharmacologic treatments improved erectile function for at least 6 months in 41% of patients with ED of varying etiologies, and was safe.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Strengths &amp; Limitations<\/jats:title>\n                    <jats:p>A relatively large cohort of patients with ED was included, with a long follow-up period, however the study was retrospective, and uncontrolled.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides preliminary evidence that BTX-A IC administered as an add-on therapy for ED that is insufficiently responsive to standard therapy is effective for at least 6 months, and is safe. Randomized clinical trials are now needed to fully confirm these results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.jsxm.2021.10.011","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T02:04:58Z","timestamp":1639965898000},"page":"83-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Long Term Effectiveness and Safety of Intracavernosal Botulinum Toxin A as an Add-on Therapy to Phosphosdiesterase Type 5 Inhibitors or Prostaglandin E1 Injections for Erectile Dysfunction"],"prefix":"10.1093","volume":"19","author":[{"given":"Francois","family":"Giuliano","sequence":"first","affiliation":[{"name":"Neuro-Uro-Andrology R.Poincare academic hospital , Garches , France"},{"name":"Faculty of Medicine, U1179 Inserm \/ Versailles Saint Quentin University, Montigny le Bretonneux, Paris Saclay , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Joussain","sequence":"additional","affiliation":[{"name":"Neuro-Uro-Andrology R.Poincare academic hospital , Garches , France"},{"name":"Faculty of Medicine, U1179 Inserm \/ Versailles Saint Quentin University, Montigny le Bretonneux, Paris Saclay , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Denys","sequence":"additional","affiliation":[{"name":"Neuro-Uro-Andrology R.Poincare academic hospital , Garches , France"},{"name":"Faculty of Medicine, U1179 Inserm \/ Versailles Saint Quentin University, Montigny le Bretonneux, Paris Saclay , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,19]]},"reference":[{"key":"2023041407161026600_","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.sxmr.2018.11.007","article-title":"Systematic review of oral combination therapy for erectile dysfunction when phosphodiesterase type 5 inhibitor monotherapy fails","volume":"7","author":"Munk","year":"2019","journal-title":"Sex Med Rev"},{"key":"2023041407161026600_","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.sxmr.2017.07.008","article-title":"Botulinum neurotoxin and its potential role in the treatment of erectile dysfunction","volume":"6","author":"Ghanem","year":"2018","journal-title":"Sex Med Rev"},{"key":"2023041407161026600_","doi-asserted-by":"crossref","first-page":"E283","DOI":"10.3390\/toxins11050283","article-title":"Safety and efficacy of intracavernosal injections of abobotulinumtoxin A (Dysport\u00ae) as add on therapy to phosphosdiesterase type 5 inhibitors or prostaglandin E1 for erectile dysfunction-case studies","volume":"11","author":"Giuliano","year":"2019","journal-title":"Toxins (Basel)"},{"key":"2023041407161026600_","doi-asserted-by":"crossref","DOI":"10.1111\/andr.13010","article-title":"Intra-Cavernous Injection of BOTOX\u00ae (50 and 100 Units) for Treatment of Vasculogenic Erectile Dysfunction: Randomized Controlled Trial","author":"El-Shaer","year":"2021"},{"key":"2023041407161026600_","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jsxm.2016.12.229","article-title":"Botox for erectile dysfunction","volume":"14","author":"Giuliano","year":"2017","journal-title":"J Sex Med"},{"key":"2023041407161026600_","doi-asserted-by":"crossref","first-page":"H2627","DOI":"10.1152\/ajpheart.00477.2002","article-title":"Botulinum neurotoxin A attenuates release of norepinephrine but not NPY from vasoconstrictor neurons","volume":"283","author":"Morris","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2023041407161026600_","first-page":"63","article-title":"The role of botulinum toxin A in treating neurogenic bladder","volume":"5","author":"Weckx","year":"2016","journal-title":"Transl Androl Urol"},{"key":"2023041407161026600_","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrn2401","article-title":"The neural control of micturition","volume":"9","author":"Fowler","year":"2008","journal-title":"Nat Rev Neurosci"},{"key":"2023041407161026600_","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/nau.23352","article-title":"Long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity","volume":"37","author":"Joussain","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"2023041407161026600_","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.juro.2016.04.046","article-title":"Long-term efficacy and safety of onabotulinumtoxin A in patients with neurogenic detrusor overactivity who completed 4 years of treatment","volume":"196","author":"Rovner","year":"2016","journal-title":"J Urol"},{"key":"2023041407161026600_","author":"Dysport"},{"key":"2023041407161026600_","author":"Botox Therapeutic"},{"key":"2023041407161026600_","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.eururo.2011.07.053","article-title":"Minimal clinically important differences in the erectile function domain of the international index of erectile function scale","volume":"60","author":"Rosen","year":"2011","journal-title":"Eur Urol"},{"key":"2023041407161026600_","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.apmr.2015.01.010","article-title":"A. Single-fiber electromyography analysis of botulinum toxin diffusion in patients with fatigue and pseudobotulism","volume":"96","author":"Ruet","year":"2015","journal-title":"Arch Phys Med Rehabil"},{"key":"2023041407161026600_","doi-asserted-by":"crossref","first-page":"e657","DOI":"10.1212\/WNL.0000000000005991","article-title":"Low-dose onabotulinumtoxin A improves urinary symptoms in noncatheterizing patients with MS","volume":"91","author":"Tullman","year":"2018","journal-title":"Neurology"},{"key":"2023041407161026600_","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","article-title":"Measurement of health status. Ascertaining the minimal clinically important difference","volume":"10","author":"Jaeschke","year":"1989","journal-title":"Control Clin Trials"},{"key":"2023041407161026600_","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jmhg.2006.08.007","article-title":"Non-responders to phosphodiesterase type 5 inhibitors: is there a second chance?","volume":"3","author":"Hatzimouratidis","year":"2006","journal-title":"J Men\u2019s Health Gender"},{"key":"2023041407161026600_","first-page":"407","article-title":"Phosphodiesterase-5 (PDE5) inhibitors In the management of erectile dysfunction","volume":"38","author":"Huang","year":"2013","journal-title":"P T"},{"key":"2023041407161026600_","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.eururo.2013.01.012","article-title":"Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis","volume":"63","author":"Yuan","year":"2013","journal-title":"Eur Urol"},{"key":"2023041407161026600_","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1111\/j.1743-6109.2010.02062.x","article-title":"Summary of the recommendations on sexual dysfunctions in men","volume":"7","author":"Montorsi","year":"2010","journal-title":"J Sex Med"},{"key":"2023041407161026600_","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ucl.2005.08.007","article-title":"Physiology of penile erection and pathophysiology of erectile dysfunction","volume":"32","author":"Dean","year":"2005","journal-title":"Urol Clin North Am"},{"key":"2023041407161026600_","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/sj.ijir.3900513","article-title":"Sympathetic pathways and adrenergic innervation of the penis","volume":"12","author":"Andersson","year":"2000","journal-title":"Int J Impot Res"},{"key":"2023041407161026600_","first-page":"31","article-title":"Comparison and overview of currently available neurotoxins","volume":"7","author":"Walker","year":"2014","journal-title":"J Clin Aesthet Dermatol"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609521007499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609521007499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/19\/1\/83\/49888825\/jsm_19_1_83.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/19\/1\/83\/49888825\/jsm_19_1_83.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T09:05:29Z","timestamp":1699952729000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/19\/1\/83\/6961185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,19]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,19]]},"published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jsxm.2021.10.011","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.741383803.793594766","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.741383803.793594847","asserted-by":"object"}]},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2022,1]]},"published":{"date-parts":[[2021,12,19]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long Term Effectiveness and Safety of Intracavernosal Botulinum Toxin A as an Add-on Therapy to Phosphosdiesterase Type 5 Inhibitors or Prostaglandin E1 Injections for Erectile Dysfunction","name":"articletitle","label":"Article Title"},{"value":"The Journal of Sexual Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsxm.2021.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021, International Society of Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}